文献速递糖尿病肥胖与代谢综合征

尿肌联蛋白水平预测2型糖尿病患者肌少症发生:日本前瞻性队列研究

Prediction of Sarcopenia Onset in Type 2 Diabetes Using Urinary Titin Levels: A Japanese Prospective Cohort Study.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究在日本2型糖尿病患者中评估基线尿肌联蛋白对肌少症发生的预测价值,每年依据AWGS 2019标准评估肌少症。444名参与者中41例发生肌少症,高肌联蛋白三分位组风险升高,校正后每SD风险比1.37(95%CI 1.05-1.77,P=0.019),支持其作为无创生物标志物。

要点

  • 高尿肌联蛋白水平与2型糖尿病患者肌少症发生风险升高相关。
  • 尿肌联蛋白每升高1个SD,肌少症风险增加37%(校正HR 1.37)。
  • 该关联在年龄≥70岁、男性、BMI<25、HbA1c≥7%等亚组中一致。

核心结论

  • 在2型糖尿病患者中,升高的尿肌联蛋白水平可预测肌少症和低肌肉力量的发生。

研究设计与样本

  • 日本前瞻性队列研究,纳入444例2型糖尿病患者,中位随访1,078天,每年依据AWGS 2019标准评估肌少症。

主要发现

  • 444例参与者中41例发生肌少症,高肌联蛋白三分位组肌少症风险升高(log-rank P=0.04)。
  • Cox模型显示尿肌联蛋白与肌少症相关(校正HR每SD 1.37,95%CI 1.05-1.77,P=0.019),亦与低肌肉力量相关。
  • 亚组分析(年龄≥70岁、男性、BMI<25 kg/m2、HbA1c≥7%、eGFR≥60 mL/min/1.73 m2)中风险估计一致(交互P>0.05)。

关键数值与推荐

  • 肌少症评估采用亚洲肌少症工作组(AWGS)2019标准。
  • 尿肌联蛋白与肌少症的校正风险比:每SD 1.37(95%CI 1.05-1.77,P=0.019)。

临床怎么用

  • 尿肌联蛋白可作为2型糖尿病患者肌少症风险的无创生物标志物,辅助早期识别高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The predictive power of urinary titin for incident sarcopenia was studied in Japanese individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Baseline urinary titin levels were measured, and sarcopenia was evaluated annually using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Kaplan-Meier curves, Cox models, and time-dependent receiver operating characteristic analyses were used to assess incident sarcopenia. RESULTS: Among 444 participants (median follow-up, 1,078 days), 41 developed sarcopenia. The high titin tertile was associated with an elevated sarcopenia risk (log-rank P = 0.04). Cox models associated titin with sarcopenia (adjusted hazard ratio per SD 1.37, 95% CI 1.05-1.77, P = 0.019) and low muscle strength. Risk estimates were consistent across subgroups, including those aged ≥70 years, men, individuals with BMI <25 kg/m2, HbA1c ≥7%, and estimated glomerular filtration rate ≥60 mL/min/1.73 m2 (P for interaction > 0.05). CONCLUSIONS: Elevated urinary titin levels predict sarcopenia and low muscle strength in individuals with type 2 diabetes, supporting its use as a noninvasive biomarker.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tanabe H, Takiguchi Y, Tsutsumi R, et al. Prediction of Sarcopenia Onset in Type 2 Diabetes Using Urinary Titin Levels: A Japanese Prospective Cohort Study. Diabetes Care. 2025. PMID: 40854208. doi:10.2337/dc25-1067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。